share
share
share

Oliver Sexton: Investment Director

Oliver Sexton

Oliver Sexton joined Midven in April 2014 to manage the Rainbow Seed Fund’s synthetic biology investments.

Prior to joining Midven, Oliver managed commercialisation of bioengineering and medical technologies At Imperial Innovations and was on the board of oncology therapeutic Acublate Ltd. Earlier in his career he held commercial and partnering roles at Ark Therapeutics.

Oliver also managed a team of biotech buy-side analysts and worked at a pharma strategy consultancy.

Oliver has a BSc in Molecular Biology/Biotechnology and an MSc in Plant Science from Bristol University.

Telephone 0121 710 1990

“Turning world-leading research into profitable companies is no simple matter, but we are now at a point where many of those technologies are suitable for broad commercial application. Rainbow Seed Fund is providing not just capital, but the expertise and the networks to maximize the chances of success in existing markets and in the new markets that synthetic biology enables.”

Oliver Sexton

Associated Companies

Relevant News

Synthace Partners With Microsoft To Bring Antha To Azure

Synthace Ltd., a London based technology company developing Antha, a high level language and operating…

read more

Gene Therapy Company Quethera Obtains Grant From Wellcome Trust Pathfinder Award Scheme

Quethera Ltd, a privately funded gene therapy company based at the Babraham Research Campus in…

read more

Cytox Announces Participation In Insight Alzheimer’s Study

Participation will aid comparison of SNP genotyping with biomarker status Cytox Ltd, an innovative developer…

read more

Dow AgroSciences, Synthace Research Collaboration to Accelerate Product Development Using High Tech Tools

Synthace and Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company (NYSE:DOW), today…

read more
show more

Case Studies

Case Study - Synthace

Synthace London-based Synthace provides next-generation software and processes to exponentially improve productivity in bioscience, enabling…

read more
show more

Blog

A Discussion with Rainbow Seed Fund’s Oliver Sexton

Oliver Sexton, MSc, is Midven’s investment director and manager of Rainbow Seed Fund’s synthetic biology…

read more

Today’s Academic Projects Are Becoming Tomorrow’s Billion Pound Companies

  When we talk about the tech revolution that is currently sweeping the industrialised world,…

read more
show more

Other Team Members